FDA
-
-
-
-
-
-
-
TransMedics clarifies tax valuation allowance impact on Q4 results
-
-
-
-
-
-
-
Needham Reiterates Buy Rating on TransMedics Group (TMDX)
-
-
-
-
-
-
-
TransMedics Group (TMDX) PT Raised to $150 at Oppenheimer
-
-
-
-
-
-
-
TransMedics Reports Fourth Quarter and Full Year 2024 Financial Results
-
-
-
-
-
-
-
Needham Starts TransMedics Group (TMDX) at Buy
-
-
-
-
-
-
-
Bridge to Life Divests Certain Assets to TransMedics
-
-
-
-
-
-
-
TransMedics Receives FDA PMA Approval of OCS™ DCD Heart Indication
-
334,271 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


